Abstract
Brolucizumab 6mg is a recently approved treatment for diabetic macular oedema (DMO). It exhibited non-inferior vision gains to aflibercept 2mg with >50% of patients maintained on 12 weekly (q12w) dosing intervals through week 52 (KESTREL and KITE pivotal studies). This analysis evaluated the lifetime costs of patients treated with brolucizumab versus those treated with aflibercept from the UK National Health Service (NHS) perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
